Related Experiment Videos
Controlling neuropathic pain in HIV
Susama Verma1, Lydia Estanislao, Letty Mintz
1Department of Neurology, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029, USA.
Current HIV/AIDS Reports
|August 11, 2005
Summary
Painful HIV-associated neuropathies, especially distal symmetrical polyneuropathy (DSP), pose challenges. Treatment selection for this nerve pain balances efficacy, safety, and cost, considering antiretroviral drug effects.
Area of Science:
- Neurology
- Infectious Diseases
- Pharmacology
Background:
- Neuropathic pain is a common complication of systemic illnesses like HIV infection.
- HIV-associated peripheral neuropathies, particularly distal symmetrical polyneuropathy (DSP), present significant diagnostic and therapeutic challenges.
- Neurotoxic antiretrovirals, especially dideoxynucleoside analogues, can cause or worsen DSP.
Purpose of the Study:
- To review current and emerging treatment options for painful HIV-associated neuropathies.
- To provide guidance on selecting pharmacologic interventions based on key criteria.
- To highlight experimental agents under investigation in clinical trials.
Main Methods:
- Literature review of neuropathic pain in HIV.
- Analysis of treatment strategies for distal symmetrical polyneuropathy (DSP).
- Evaluation of efficacy, safety, administration, and cost of pharmacologic interventions.
Main Results:
- Distal symmetrical polyneuropathy (DSP) is the most frequent HIV-associated neuropathy.
- Treatment decisions for painful neuropathy require careful consideration of drug-induced nerve damage.
- Various pharmacologic options exist, with ongoing research into novel therapies.
Conclusions:
- Effective management of painful HIV neuropathy necessitates a comprehensive approach.
- Selection of treatments should prioritize patient outcomes and drug safety profiles.
- Further research and clinical trials are crucial for advancing therapeutic options.